Jane Street
PGNX

Jane Street’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Jane Street’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,600
Closed -$73K – 6101
2018
Q3 		$73K Buy
+11,600
New +$89.1K ﹤0.01% 4892

Other funds holding PGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Jane Street's PGNX Position: Q1 2020 in Review

Jane Street sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2020, closing a stake of 12,178 shares — an estimated $62K sold.

Jane Street first reported a position in PGNX in Q2 2013 and held it in 13 quarters. The position peaked at $476K in Q1 2017. 129 funds tracked by Wall St. Rank hold PGNX as of Q1 2020.

  • Jane Street reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2020 after selling out during the quarter.
  • Jane Street sold 12,178 Progenics Pharmaceuticals Inc shares in Q1 2020, an estimated $62K.
  • Jane Street first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 13 quarters.
  • Jane Street's Progenics Pharmaceuticals Inc position peaked at $476K in Q1 2017.
  • 129 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2020.

Based on Jane Street's 13F filing for Q1 2020, filed 15 May 2020.